Patents by Inventor Bolin Qin
Bolin Qin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10894030Abstract: Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of an active ingredient by weight. The active ingredient includes cinnamtannin D1 and/or cinnamtannin B1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein in the subject by the step of administering.Type: GrantFiled: September 13, 2017Date of Patent: January 19, 2021Assignee: IN Ingredients, Inc.Inventors: Augustin T. Romero, Bolin Qin
-
Patent number: 10842774Abstract: Processes for treating an autoimmune disease or condition by decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.Type: GrantFiled: October 15, 2019Date of Patent: November 24, 2020Assignee: IN Ingredients, Inc.Inventors: Augustin T. Romero, Bolin Qin
-
Publication number: 20200054597Abstract: Processes for treating an autoimmune disease or condition by decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.Type: ApplicationFiled: October 15, 2019Publication date: February 20, 2020Inventors: Augustin Romero, Bolin Qin
-
Patent number: 10478418Abstract: Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.Type: GrantFiled: September 12, 2018Date of Patent: November 19, 2019Assignee: IN Ingredients, Inc.Inventors: Augustin T. Romero, Bolin Qin
-
Publication number: 20190076393Abstract: Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of an active ingredient by weight. The active ingredient includes cinnamtannin D1 and/or cinnamtannin B1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein in the subject by the step of administering.Type: ApplicationFiled: September 13, 2017Publication date: March 14, 2019Inventors: Augustin T. Romero, Bolin Qin
-
Publication number: 20190076397Abstract: Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.Type: ApplicationFiled: September 12, 2018Publication date: March 14, 2019Inventors: Augustin T. Romero, Bolin Qin
-
Publication number: 20180296522Abstract: Processes for increasing expression of a MTOR gene or a mTOR protein or decreasing expression of a MSTN gene or a myostatin protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% Type-A polymers by weight. The Type-A polymers include A-Type doubly-linked procyanidin oligomers of the catechins and/or epicatechins. The processes further include increasing expression of a MTOR gene or a mTOR protein or decreasing expression of a MSTN gene or a myostatin protein in the subject by the step of administering.Type: ApplicationFiled: November 6, 2015Publication date: October 18, 2018Applicant: IN Ingredients, Inc.Inventors: Bolin Qin, Augustin T. Romero
-
Patent number: 10058579Abstract: A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.Type: GrantFiled: May 26, 2011Date of Patent: August 28, 2018Assignee: IN Ingredients, Inc.Inventors: Peter J. Miller, Tim Romero, Bolin Qin, Augustin T. Romero
-
Patent number: 10039798Abstract: Provided are process of regulating expression of one or more genes or proteins involved in circadian rhythm. A subject such as a cell is administered or contacted to an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active agents in the extracts administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.Type: GrantFiled: November 13, 2014Date of Patent: August 7, 2018Assignee: IN Ingredients, Inc.Inventors: Bolin Qin, Augustin T. Romero, Tim Romero
-
Publication number: 20180064778Abstract: Processes are provided for altering an expression of a mood condition or disorder in a subject without a sleep disorder includes administering to the subject without a sleep disorder in need thereof an effective amount of an extract of rosemary, an extract of Hemerocallis fulva, an active component thereof, or combinations thereof at an administration time.Type: ApplicationFiled: September 1, 2017Publication date: March 8, 2018Inventors: Bolin Qin, Augustin T. Romero, Tim Romero
-
Publication number: 20160296581Abstract: Provided are process of regulating expression of one or more genes or proteins involved in circadian rhythm. A subject such as a cell is administered or contacted to an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active agents in the extracts administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.Type: ApplicationFiled: November 13, 2014Publication date: October 13, 2016Inventors: Bolin Qin, Augustin T. Romero, Tim Romero
-
Publication number: 20160256511Abstract: Provided are compositions and processes of treating or preventing one or more conditions related to a protein involved in circadian rhythm. A composition includes an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active ingredients in the extracts optionally administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.Type: ApplicationFiled: November 13, 2014Publication date: September 8, 2016Inventors: Bolin Qin, Augustin T. Romero, Tim Romero
-
Publication number: 20140072659Abstract: Materials derived from Nelumbo are administered orally to humans or animals for the purpose of enhancing creatine transport into skeletal tissue and for purposes of enhancing lean body mass. Enhancing creatine transport through improved insulin signaling is a new method of depositing creatine and enhancing lean body mass. Such administration is also used for enhancing athletic performance and controlling bodyweight and body fat levels. More specifically, such administration is used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material is administered as extracts of Nelumbo and administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.Type: ApplicationFiled: November 12, 2013Publication date: March 13, 2014Applicant: FHG Corporation d/b/a Integrity NutraceuticalsInventors: Tim Romero, Peter J. Miller, Bolin Qin
-
Patent number: 8613959Abstract: Materials derived from Nelumbo are administered orally to humans or animals for the purpose of enhancing creatine transport into skeletal tissue and for purposes of enhancing lean body mass. Enhancing creatine transport through improved insulin signaling is a new method of depositing creatine and enhancing lean body mass. Such administration is also used for enhancing athletic performance and controlling bodyweight and body fat levels. More specifically, such administration is used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material is administered as extracts of Nelumbo and administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.Type: GrantFiled: February 9, 2010Date of Patent: December 24, 2013Assignee: FHG CorporationInventors: Tim Romero, Peter Miller, Bolin Qin
-
Patent number: 8445035Abstract: A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss.Type: GrantFiled: November 28, 2011Date of Patent: May 21, 2013Assignee: FHG CorporationInventors: Timothy Romero, Bolin Qin, Peter J. Miller
-
Publication number: 20130072574Abstract: A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.Type: ApplicationFiled: May 26, 2011Publication date: March 21, 2013Applicant: FHG CORPORATION D/B/A INTEGRITY NUTRACEUTICALSInventors: Peter J. Miller, Tim Romero, Bolin Qin, Augustin T. Romero
-
Publication number: 20120128800Abstract: A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss.Type: ApplicationFiled: November 28, 2011Publication date: May 24, 2012Applicant: FHG Corporation d/b/a Integrity NutraceuticalsInventors: Timothy J. Romero, Bolin Qin, Peter J. Miller
-
Patent number: 8158683Abstract: A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss.Type: GrantFiled: May 20, 2009Date of Patent: April 17, 2012Assignee: FHG CorporationInventors: Timothy J. Romero, Bolin Qin, Peter J. Miller
-
Publication number: 20100227007Abstract: Materials derived from Nelumbo are administered orally to humans or animals for the purpose of enhancing creatine transport into skeletal tissue and for purposes of enhancing lean body mass. Enhancing creatine transport through improved insulin signaling is a new method of depositing creatine and enhancing lean body mass. Such administration is also used for enhancing athletic performance and controlling bodyweight and body fat levels. More specifically, such administration is used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material is administered as extracts of Nelumbo and administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.Type: ApplicationFiled: February 9, 2010Publication date: September 9, 2010Inventors: Tim Romero, Peter Miller, Bolin Qin
-
Publication number: 20100222422Abstract: A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition. The dietary supplement composition is administered orally to promote weight loss.Type: ApplicationFiled: May 20, 2009Publication date: September 2, 2010Applicant: F.H.G. Corporation,d/b/a Integrity NutraceuticalsInventors: Timothy J. ROMERO, Bolin QIN, Peter J. MILLER